← Back to Patent Explorer
US4818690A Expired / Lapsed US ⏱️ 0.0 years remaining

Method for the determination of plasminogen activators (PA)

Assignee: Siemens Healthcare Diagnostics GmbH Germany
•
Filing: 1986-04-09
•
Granted: 1989-04-04
•
Expires: 2006-04-09
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract A method for the determination of urokinase (UK) or tissue plasminogen activator (t-PA) is described, in which the activator is incubated with plasminogen, with a polysulfuric ester of a saccharide or with a sulfated sugar and, where appropriate, fibrin or fibrin degradation products, and the conversion of plasminogen into plasmin is determined, and agents suitable for this method are described.

Inventors

  • 👤 Eric P. Paques

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-11-07 10:10
CPC Classifications
C; C12; C12Q; C12Q1/00; C12Q1/56; C12Q2337/00; C12Q2337/10; C12Q2337/12; G; G01; G01N; G01N2333/00; G01N2333/90; G01N2333/914; G01N2333/948; G01N2333/968; G01N2333/972; G01N2333/9723; G01N2333/9726; G01N2400/00; G01N2400/10; G01N2400/38; G01N2400/40

Claims Analysis

Total Claims: 13
Claim 1
Independent Claim 68 words
A method for the quantitative determination of a plasminogen activator (PA) from the group consisting of urokinase (UK) and tissue plasminogen activator (tPA) in body fluids, which comprises the steps of incubating PA with plasminogen and with a polysulfuric ester of a saccharide or with a sulfated sugar under conditions effective to allow conversion of the plasminogen into plasmin; and determining quantitatively the conversion of plasminogen into plasmin.
Claim 2
Independent Claim 68 words
A method for the quantitative determination of a plasminogen activator (PA) from the group consisting of urokinase (UK) and tissue plasminogen activator (tPA) in body fluids, which comprises the steps of incubating PA with plasminogen and with a polysulfuric ester of a saccharide or with a sulfated sugar under conditions effective to allow conversion of the plasminogen into plasmin; and determining quantitatively the conversion of plasminogen into plasmin.
Claim 3
Dependent Claim 21 words
The method of claim 1, wherein said incubating step is further conducted in the presence of fibrin or fibrin degredation products.
Claim 4
Dependent Claim 20 words
The method of claim 2, wherein the determining step is further conducted with the use of a chromogenic substrate indicator.
Claim 5
Dependent Claim 25 words
The method as claimed in claim 3, wherein cell membrane constituents are used as the polysulfuric ester of a saccharide or as the sulfated sugar.
Claim 6
Dependent Claim 13 words
The method as claimed in claim 3, wherein the plasminogen activator is t-PA.
Claim 7
Dependent Claim 16 words
The method as claimed in claim 3, wherein the polysulfuric ester of a saccharide is heparin.
Claim 8
Dependent Claim 23 words
The method as claimed in claim 3, wherein heparin is used in a concentration of 10 -8 to 1 mg/ml of assay mixture.
Claim 9
Dependent Claim 45 words
The method as claimed in claim 3, wherein the polysulfuric ester of a saccharide or the sulfated sugar is heparan sulfate, dermatan sulfate, chondroitin sulfate, pentosan sulfate, keratan sulfate or mucopolysaccharide polyslfate, in a concentration of 10 -8 to 1 mg/ml in the assay mixture.
Claim 10
Dependent Claim 30 words
An agent for the quantitative determination of a plasminogen activator comprising at least from about 0.01 to about 1 CTA/ml plasminogen and from about 10 -4 to 1 g/ml heparin.
Claim 11
Dependent Claim 30 words
An agent for the quantitative determination of a plasminogen activator comprising at least from about 0.01 to about 1 CTA/ml plasminogen and from about 10 -4 to 1 g/ml heparin.
Claim 12
Dependent Claim 18 words
The agent of claim 9 further comprising from about 0.01 to about 0.1 ml/100 ml polyoxyethylene sorbitan monooleate.
Claim 13
Dependent Claim 10 words
The agent of claim 10 further comprising fibrin degradation products.

References Cited (Backward Citations)

US4011142A Cited
US4033824A Cited
US4605614A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1992-04-03 1992-10-03 1993-04-04 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1996-04-03 1996-10-03 1997-04-04 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 2000-04-03 2000-10-03 2001-04-04 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag